JP2023515566A5 - - Google Patents

Info

Publication number
JP2023515566A5
JP2023515566A5 JP2022551273A JP2022551273A JP2023515566A5 JP 2023515566 A5 JP2023515566 A5 JP 2023515566A5 JP 2022551273 A JP2022551273 A JP 2022551273A JP 2022551273 A JP2022551273 A JP 2022551273A JP 2023515566 A5 JP2023515566 A5 JP 2023515566A5
Authority
JP
Japan
Application number
JP2022551273A
Other languages
Japanese (ja)
Other versions
JPWO2021174091A5 (https=
JP7751590B2 (ja
JP2023515566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020039 external-priority patent/WO2021174091A1/en
Publication of JP2023515566A publication Critical patent/JP2023515566A/ja
Publication of JPWO2021174091A5 publication Critical patent/JPWO2021174091A5/ja
Publication of JP2023515566A5 publication Critical patent/JP2023515566A5/ja
Application granted granted Critical
Publication of JP7751590B2 publication Critical patent/JP7751590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022551273A 2020-02-28 2021-02-26 トランスグルタミナーゼ媒介コンジュゲーション Active JP7751590B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062983463P 2020-02-28 2020-02-28
US62/983,463 2020-02-28
US202063110854P 2020-11-06 2020-11-06
US63/110,854 2020-11-06
PCT/US2021/020039 WO2021174091A1 (en) 2020-02-28 2021-02-26 Transglutaminase-mediated conjugation

Publications (4)

Publication Number Publication Date
JP2023515566A JP2023515566A (ja) 2023-04-13
JPWO2021174091A5 JPWO2021174091A5 (https=) 2024-03-05
JP2023515566A5 true JP2023515566A5 (https=) 2024-03-05
JP7751590B2 JP7751590B2 (ja) 2025-10-08

Family

ID=77490350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551273A Active JP7751590B2 (ja) 2020-02-28 2021-02-26 トランスグルタミナーゼ媒介コンジュゲーション

Country Status (11)

Country Link
US (4) US11920136B2 (https=)
EP (1) EP4110830A4 (https=)
JP (1) JP7751590B2 (https=)
KR (1) KR20220162130A (https=)
CN (1) CN115427458A (https=)
AU (1) AU2021226023A1 (https=)
BR (1) BR112022017136A2 (https=)
CA (1) CA3169523A1 (https=)
IL (1) IL295759A (https=)
MX (1) MX2022010515A (https=)
WO (1) WO2021174091A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
BR112022017136A2 (pt) 2020-02-28 2022-10-11 Tallac Therapeutics Inc Conjugação mediada por transglutaminase
US20230364255A1 (en) * 2020-08-18 2023-11-16 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
US11795500B2 (en) 2021-08-19 2023-10-24 Eclipse Bioinnovations, Inc. Methods for detecting RNA binding protein complexes
KR20240083868A (ko) * 2021-08-20 2024-06-12 탈락 테라퓨틱스, 인크. 넥틴-4 항체 및 접합체
MX2024002407A (es) * 2021-08-25 2024-05-15 Tallac Therapeutics Inc Anticuerpos y conjugados sirp-alfa.
EP4201430A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Modified antibody for site-specific conjugation and its diagnostic use
EP4201956A1 (en) 2021-12-23 2023-06-28 F. Hoffmann-La Roche AG Kutzneria albida (kalbtg) transglutaminase used for antibody conjugations
WO2023129970A2 (en) * 2021-12-30 2023-07-06 Eclipse Bioinnovations, Inc. Methods for detecting rna translation
CN119546345A (zh) * 2022-05-18 2025-02-28 塔拉克治疗公司 使用抗cd22抗体寡核苷酸缀合物治疗癌症的方法
CN119584993A (zh) 2022-07-20 2025-03-07 豪夫迈·罗氏有限公司 用于位点特异性抗体缀合的接头
WO2024238558A1 (en) * 2023-05-15 2024-11-21 Tallac Therapeutics, Inc. Use of immunomodulating targeted polynucleotide conjugates for use with immune honing agent
WO2025081048A1 (en) * 2023-10-13 2025-04-17 Tallac Therapeutics, Inc. Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates
WO2025157804A1 (en) 2024-01-24 2025-07-31 F. Hoffmann-La Roche Ag Linkers for site-specific protein conjugation
WO2026008881A1 (en) 2024-07-05 2026-01-08 Synaffix B.V. Extracellular vesicles comprising biomolecule-conjugates

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU598946B2 (en) 1987-06-24 1990-07-05 Howard Florey Institute Of Experimental Physiology And Medicine Nucleoside derivatives
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US7982011B2 (en) * 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
US20080031887A1 (en) * 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
EP2170353B1 (en) 2007-05-18 2015-06-03 AdiuTide Pharmaceuticals GmbH Phosphate-modified oligonucleotide analogs with immunostimulatory activity
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9650427B2 (en) 2011-07-22 2017-05-16 Children's Medical Center Corporation Modulators of antiviral signaling pathways and therapeutic uses thereof
AP2014007595A0 (en) 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
KR20150030698A (ko) 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
KR102165464B1 (ko) * 2012-07-19 2020-10-14 레드우드 바이오사이언스 인코포레이티드 Cd22에 대해 특이적인 항체 및 이들의 사용 방법
CA2886433C (en) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
PL2931738T3 (pl) 2012-12-13 2019-07-31 Aduro Biotech, Inc. Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania
WO2014179335A1 (en) 2013-04-29 2014-11-06 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
AU2014346658A1 (en) 2013-11-06 2016-06-02 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
US10556024B2 (en) * 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
TW201623265A (zh) 2014-05-09 2016-07-01 奇尼塔公司 抗病毒化合物、醫藥組合物及其使用方法
JP2017522046A (ja) 2014-06-06 2017-08-10 ソルスティス バイオロジクス,リミティッド 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
KR102524920B1 (ko) 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
US20180134802A1 (en) 2016-01-08 2018-05-17 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
WO2016079899A1 (ja) 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途
JP6864953B2 (ja) 2014-12-09 2021-04-28 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Axlに対するヒトモノクローナル抗体
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導rig-i和其他模式辨識受體之化合物及組成物
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
BR112018005322A2 (pt) 2015-09-18 2018-12-11 Arch Oncology, Inc. anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
AU2016365828A1 (en) 2015-12-08 2018-07-05 Solstice Biologics, Ltd. Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
WO2017143171A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
SG11201808465UA (en) 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
AR112048A1 (es) 2016-05-09 2019-09-18 Celgene Corp Anticuerpos cd47 y métodos de uso de los mismos
JP6979971B2 (ja) 2016-05-09 2021-12-15 アイジーエム バイオサイエンシズ インコーポレイテッド 抗pd−l1抗体
CN108350082B (zh) 2016-06-13 2021-09-24 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
CN109414500B (zh) 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
CN106084052B (zh) 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
KR102878970B1 (ko) 2016-08-03 2025-10-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
MX2019012295A (es) * 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
CA3103265A1 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
JP7536025B2 (ja) 2018-10-17 2024-08-19 タラック セラピューティクス,インク. 免疫調節性ポリヌクレオチドコンジュゲートと使用方法
BR112022017136A2 (pt) 2020-02-28 2022-10-11 Tallac Therapeutics Inc Conjugação mediada por transglutaminase
US20230364255A1 (en) 2020-08-18 2023-11-16 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation

Similar Documents

Publication Publication Date Title
CN305536814S (https=)
CN306539731S (https=)
CN305841247S (https=)
CN305866735S (https=)
CN305867886S (https=)
CN305869466S (https=)
CN305870077S (https=)
CN305876283S (https=)
CN305880499S (https=)
CN305883333S (https=)
CN305903232S (https=)
CN305904329S (https=)
CN305905564S (https=)
CN305906813S (https=)
CN305907452S (https=)
CN305908904S (https=)
CN305912779S (https=)
CN305916101S (https=)
CN305916359S (https=)
CN305917387S (https=)
CN305917807S (https=)
CN305927040S (https=)
CN305927580S (https=)
CN305928756S (https=)
CN305952385S (https=)